Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Nature communications·2026
Same author

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

European urology·2026
Same author

CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors.

Frontiers in immunology·2026
Same author

CAR-NK Engineering to Overcome TME Barriers.

Cells·2026
Same author

CRISPR-Cas9 knockout of DGKα/ζ improves the anti-tumor activities of TAG-72 CAR-T cells in ovarian cancer.

Molecular therapy. Oncology·2025
Same author

Investigating the effects of global gene knockout of MrgF on motor performance and pain sensitivity in mice.

Hereditas·2025

相关实验视频

Updated: Sep 13, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

工程TAG-72和CD30CAR-T细胞用于T细胞恶性瘤.

Van To1,2, Vera J Evtimov1,2, Runzhe Shu1,2

  • 1Cartherics Pty Ltd, Notting Hill, Victoria, Australia.

Immunological investigations
|August 1, 2025
PubMed
概括

化学抗原受体 (CAR) -T细胞疗法在T细胞恶性瘤中显示出前景. 用CAR-T细胞向TAG-72和CD30抗原证明了有效性,特别是在攻击性癌症的联合治疗中.

关键词:
在CART-T中,我们可以使用CAR-T.CD3030 是一个CD3030 是一个CD30.在T细胞淋巴瘤.在TAG-72中.聚合的CARCAR是一个聚合的CAR.

更多相关视频

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.1K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

相关实验视频

Last Updated: Sep 13, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.1K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法

背景情况:

  • 恶性T细胞瘤是一个多样化的淋巴瘤群体,结果不佳.
  • 化学抗原受体 (CAR) -T细胞疗法对B细胞淋巴瘤有效,但由于目标稀缺性和异质性,T细胞淋巴瘤面临挑战.
  • 确定有效的CAR-T细胞点对于改善T细胞恶性瘤治疗至关重要.

研究的目的:

  • 开发和评估针对瘤关联糖蛋白72 (TAG-72) 的CAR-T细胞,以及针对T细胞恶性瘤的C-C化学因子受体4型 (CCR4) 和CD30.
  • 在体外评估这些CAR-T细胞的抗瘤疗效.
  • 探索双重准策略的潜力.

主要方法:

  • 开发和表征三个不同的CAR-T细胞系,针对TAG-72,CCR4和CD30.
  • 在体外评估CAR-T细胞扩张和对T细胞恶性瘤的细胞毒性功能.
  • 评估用于双抗原向的聚合CAR-T细胞.

主要成果:

  • TAG-72和CD30 CAR-T细胞表现出类似的扩张,并有效地消除了向抗原表达瘤细胞.
  • 对TAG-72和CD30CAR-T细胞的双重向显示出增强的细胞毒性功能,特别是当向抗原表达低时.
  • 流细胞计证实了影响CAR-T细胞疗效的抗原表达水平.

结论:

  • 针对TAG-72和CD30的CAR-T细胞代表了T细胞恶性瘤的有前途的治疗策略.
  • 组合或双向的CAR-T细胞疗法具有治疗侵略性T细胞淋巴瘤的潜力.
  • 对于T细胞恶性瘤,对新的CAR-T细胞点和策略进行进一步的研究是有必要的.